Quality of life, anxiety and depression in adult patients after add-on of levetiracetam and conversion to levetiracetam monotherapy

Epilepsy Research

Volumn 104, Issue 1-2, 2013, Pages 140-150

  Hagemann, Anne ^a,b   May, Theodor W ^b   Nieder, Esther ^c   Witte Bölt, Karin ^b   Pohlmann Eden, Bernd ^d   Elger, Christian E ^e   Tergau, Frithjof ^f   Schulze Bonhage, Andreas ^g   Straub, Hans Beatus ^h   Arnold, Stephan ⁱ   Brandt, Christian ^b,c  

^a BIELEFELD UNIVERSITY   (Germany)

^b Society for Epilepsy Research   (Germany)

^c EPILEPSY CENTER BETHEL   (Germany)

^d DALHOUSIE UNIVERSITY   (Canada)

^e UNIVERSITY HOSPITAL BONN   (Germany)

^f St Bernward Hospital   (Germany)

^g UNIVERSITY OF FREIBURG   (Germany)

^h Epilepsy Centre Berlin Brandenburg   (Germany)

ⁱ Neurological Practice   (Germany)

Author keywords

Anxiety; Depression; Levetiracetam; Monotherapy; Quality of life

Indexed keywords

ANTICONVULSIVE AGENT; ETIRACETAM;

ADD ON THERAPY; ADULT; ANXIETY; ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG WITHDRAWAL; EPILEPSY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PATIENT SATISFACTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; SEIZURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; ANTICONVULSANTS; ANXIETY; DEPRESSION; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED; PIRACETAM; PROSPECTIVE STUDIES; QUALITY OF LIFE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84875493996     PISSN: 09201211     EISSN: 18726844     Source Type: Journal    
DOI: 10.1016/j.eplepsyres.2012.08.005     Document Type: Article

References (37)

1. Ben-Menachem E., Falter U. Efficacy and tolerability of levetiracetam 3000mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group. Epilepsia 2000, 41:1276-1283.
2. Bjelland I., Dahl A.A., Haug T.T., Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. J. Psychosom. Res. 2002, 52:69-77.
3. Brandt C., Nieder E., Hagemann A., Witte-Boelt K., Pohlmann-Eden B., Elger C., Tergau F., Schulze-Bonhage A., Straub H.B., Arnold S., May T.W. Conversion to monotherapy with Levetiracetam in patients with focal or generalized epilepsy - first results of a prospective, open and investiagtor-initiated multicenter study. Epilepsia 2010, 51:18-19.
4. Brandt C., Schoendienst M., Trentowska M., May T.W., Pohlmann-Eden B., Tuschen-Caffier B., Schrecke M., Fueratsch N., Witte-Boelt K., Ebner A. Prevalence of anxiety disorders in patients with refractory focal epilepsy - a prospective clinic based survey. Epilepsy Behav. 2010, 17:259-263.
5. Brodie M.J., Perruca E., Ryvlin P., Ben-Menachem E., Meencke H.J., Levetiracetam Monotherapy Study Group Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007, 68:402-408.
6. Cereghino J.J., Biton V., AbouKhalil B., Dreifuss F., Gauer L.J., Leppik I. Levetiracetam for partial seizures - results of a double-blind, randomized clinical trial. Neurology 2000, 55:236-242.
7. Ciesielski A.S., Samson S., Steinhoff B.J. Neuropsychological and psychiatric impact of add-on titration of pregabalin versus levetiracetam: a comparative short-term study. Epilepsy Behav. 2006, 9:424-431.
8. Cohen J. Statistical Power Analysis for the Behavioral Sciences 1988, Lawrence Erlbaum Associates, Hillsdale, NJ. 2nd edition.
9. Cramer J.A., Arrigo C., VanHammee G., Gauer L.J., Cereghino J.J. Effect of levetiracetam on epilepsy-related quality of life. Epilepsia 2000, 41:868-874.
10. Cramer J.A., Brandenburg N., Xu X. Differentiating anxiety and depression symptoms in patients with partial epilepsy. Epilepsy Behav. 2005, 6:563-569.
11. Cramer J.A., Hammer A.E., Kustra R.P. Quality of life improvement with conversion to lamotrigine monotherapy. Epilepsy Behav. 2004, 5:224-230.
12. Cramer J.A., Perrine K., Devinsky O., Bryant-Comstock L., Meador T., Hermann B. Development and cross-cultural translations of a 31-item quality of life in epilepsy inventory. Epilepsia 1998, 39:81-88.
13. Cramer J.A., Van Hammee G. Maintenance of improvement in health-related quality of life during long-term treatment with levetiracetam. Epilepsy Behav. 2003, 4:118-123.
14. Deckers C.L., Hekster Y.A., Keyser A., van Lier H.J., Meinardi H., Renier W.O. Monotherapy versus polytherapy for epilepsy: a multicenter double-blind randomized study. Epilepsia 2001, 42:1387-1394.
15. De Smedt T., Raedt R., Vonck K., Boon P. Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug. CNS Drug Rev. 2007, 13:57-78.
16. Elsharkawy A.E., Thorbecke R., Ebner A., May T.W. Determinants of quality of life in patients with refractory focal epilepsy who were not eligible for surgery or who rejected surgery. Epilepsy Behav. 2012, 24:249-255.
17. Gilliam F., Vazquez B., Sackellares J.C., Chang G.Y., Messenheimer J., Nyberg J., Risner M.E., Rudd G.D. An active-control trial of lamotrigine monotherapy for partial seizures. Neurology 1998, 51:1018-1025.
18. Guberman A. Monotherapy or polytherapy for epilepsy?. Can. J. Neurol. Sci. 1998, 25:S3-S8.
19. Harden C.L. Depression and anxiety in epilepsy patients. Epilepsy Behav. 2002, 3:296.
20. Herrmann C. International experiences with the Hospital Anxiety and Depression Scale - a review of validation data and clinical results. J. Psychosom. Res. 1997, 42:17-41.
21. Herrmann C., Buss U., Snaith R.P. HADS-D Hospital Anxiety and Depression Scale - Deutsche Version 1995, Hans Huber, Bern.
22. Lee J.J., Song H.S., Hwang Y.H., Lee H.W., Suh C.K., Park S.P. Psychiatric symptoms and quality of life in patients with drug-refractory epilepsy receiving adjunctive levetiracetam therapy. J. Clin. Neurol. 2011, 7:128-136.
23. Lopez-Gongora M., Martinez-Domeno A., Garcia C., Escartin A. Effect of levetiracetam on cognitive functions and quality of life: a one-year follow-up study. Epileptic. Disord. 2008, 10:297-305.
24. Mazza M., Martini A., Scoppetta M., Mazza S. Effect of levetiracetam on depression and anxiety in adult epileptic patients. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:539-543.
25. May T.W., Pfafflin M., Cramer J.A. Psychometric properties of the German translation of the QOLIE-31. Epilepsy Behav. 2001, 2:106-114.
26. Mensah S.A., Beavis J.M., Thapar A.K., Kerr M. The presence and clinical implications of depression in a community population of adults with epilepsy. Epilepsy Behav. 2006, 8:213-219.
27. Mensah S.A., Beavis J.M., Thapar A.K., Kerr M.P. A community study of the presence of anxiety disorder in people with epilepsy. Epilepsy Behav. 2007, 11:118-124.
28. Morrell M.J., Leppik I., French J., Ferrendelli J., Han J., Magnus L. The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study. Epilepsy Res. 2003, 54:153-161.
29. Mula M., Sander J.W. Suicidal ideation in epilepsy and levetiracetam therapy. Epilepsy Behav. 2007, 11:130-132.
30. Mula M., Trimble M.R., Yuen A., Liu R.S., Sander J.W. Psychiatric adverse events during levetiracetam therapy. Neurology 2003, 61:704-706.
31. Noachtar S., Andermann E., Meyvisch P., Andermann F., Gough W.B., Schiemann-Delgado J., N166 Levetiracetam Study Group Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 2008, 70:607-616.
32. Pirio Richardson S., Farias S.T., Lima 3rd A.R., Alsaadi T.M. Improvement in seizure control and quality of life in medically refractory epilepsy patients converted from polypharmacy to monotherapy. Epilepsy Behav. 2004, 5:343-347.
33. Souza E.A.P., Salgado P.C.B. A psychosocial view of anxiety and depression in epilepsy. Epilepsy Behav. 2006, 8:232-238.
34. Steinhoff B.J., Somerville E.R., Van Paesschen W., Ryvlin P., Schelstraete I. The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy. Epilepsy Res. 2007, 76:6-14.
35. Weintraub D., Buchsbaum R., Resor S.R. Psychiatric and behavioral side effects of the newer antiepileptic drugs in adults with epilepsy. Epilepsy Behav. 2007, 10:105-110.
36. White J.R., Walczak T.S., Leppik I.E., Rarick J., Tran T., Beniak T.E., Matchinsky D.J., Gumnit R.J. Discontinuation of levetiracetam because of behavioral side effects: a case-control study. Neurology 2003, 61:1218-1221.
37. Wiebe S., Matijevic S., Eliasziw M., Derry P.A. Clinically important change in quality of life in epilepsy. J. Neurol. Neurosurg. Psychiatry 2002, 73:116-120.